PRX302

Phase 2Small molecule

SSophiris Bio Corp

PRX302 is one of 74 small molecule programs targeting Hyperplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaActive, not recruiting

Benign Prostatic HyperplasiaActive, not recruiting

Prostate CancerActive, not recruiting

HyperplasiaPhase 2

Active, not recruiting

Benign Prostatic HyperplasiaPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

PRX302

SSophiris Bio Corp

Phase 2

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Completed·SSophiris Bio Corp·Phase 2·NCT02499848·18 enrolled

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Completed·SSophiris Bio Corp·Phase 2·NCT03081481·38 enrolled

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Completed·SSophiris Bio Corp·Phase 2·NCT00686088·30 enrolled

Hyperplasia1 trial

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

Completed·SSophiris Bio Corp·Phase 2·NCT00889707·92 enrolled

Safety and Efficacy1 trial

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

Completed·SSophiris Bio Corp·Phase 3·NCT01966614·479 enrolled

Benign Prostatic Hyperplasia1 trial

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Completed·SSophiris Bio Corp·Phase 1/2·NCT01454349·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PRX302. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRX302 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRX302. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sophiris Bio Corp company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSophiris Bio Corp

PRX302

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer3 trials

Hyperplasia1 trial

Safety and Efficacy1 trial

Benign Prostatic Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News